Gene Therapy Shows Early Potential in XLRP

Podcast

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

At the American Society of Retina Specialists (ASRS) 2020 Virtual Sessions this weekend, phase 1/2 data from a novel assessment of investigative gene therapy AAV-RGPR showed early safety and tolerability among patients with X-linked retinitis pigmentosa (XLRP).

The findings, from a team of Janssen and Meira GTx investigators, could have significant implications for the XLRP treatment field. Currently, no drugs are approved by the US Food and Drug Administration (FDA) for the disease which causes debilitating vision in boys and young men.

Additionally, the new findings add fodder to the greater discussion of gene therapy in ophthalmology.

In alignment with the new ASRS 2020 data, AAV-RGPR primary investigator Michel Michaelides, MD, joined DocTalk for a discussion on the early trial findings, the burden of disease among patients with XLRP, and what promises are held for gene therapy in ophthalmology.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.